Last reviewed · How we verify
amyloid PET
Amyloid PET is a diagnostic imaging agent that binds to amyloid beta plaques in the brain.
Amyloid PET is a diagnostic imaging agent that binds to amyloid beta plaques in the brain. Used for Diagnosis of Alzheimer's disease and other amyloid-related conditions.
At a glance
| Generic name | amyloid PET |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Target | Amyloid beta |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Amyloid PET works by using a radioactive tracer that selectively binds to amyloid beta plaques, allowing for visualization of amyloid deposition in the brain. This can help diagnose and monitor Alzheimer's disease and other amyloid-related conditions.
Approved indications
- Diagnosis of Alzheimer's disease and other amyloid-related conditions
Common side effects
- Radiation exposure
Key clinical trials
- Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People (EARLY_PHASE1)
- Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
- Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis (PHASE1)
- Alzheimer's Disease Neuroimaging Initiative 4
- Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study
- Longitudinal Imaging Biomarkers of Disease Progression in DLB (PHASE4)
- Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis (PHASE1, PHASE2)
- Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |